Please assess the completion status of the following clinical trial:

Trial Title: A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Meet 4 of 6 criteria of 2002 American-European Consensus Group (AECG) criteria for Primary Sjogren's Syndrome~2. Presence of anti Ro autoantibodies~3. Presence of interferon signature~Exclusion Criteria:~1. Use fo hydroxychloroquine within 30 days of baseline~2. Use of cyclophosphamide within 180 days of baseline~3. Use of oral corticosteroids greater than 10 mg/day~4. Known IgG4-related disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- RSLV-132 (Type: ACTIVE_COMPARATOR): Experimental drug

Based on this trial design, predict the completion outcome and termination type (if applicable).